18 completed, 15 recruiting, 14 active not recruiting, 10 not yet recruiting. 32 Phase 2, 12 Phase 3, 5 Phase 4, 4 Phase 1, 3 Not applicable.
Follow luspatercept: new trials by email Literature Review of luspatercept trials Research Report on luspatercept
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Emavusertib - Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 270 | 2026-12-18 | 2026-09-22 |
| Plasmatic Biomarkers Associated With Short-term Luspatercept Treatment of Lower Risk Myelodysplastic Syndromes (MDS) Patients Luspatercept - Myelodysplasia | Phase 4 | Not yet recruiting | University Hospital, Grenoble | 150 | 2026-11-01 | 2026-09-21 |
| Efficacy and Safety of Maximum Labeled Dose Luspatercept in Lower-Risk Myelodysplastic Syndromes Luspatercept - Myelodysplastic Syndromes | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 75 | 2026-10-31 | 2026-10-26 |
| First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms Luspatercept - Myelodysplastic Neoplasms | Not yet recruiting | Bristol-Myers Squibb | 190 | 2026-08-24 | 2026-08-07 | |
| A Study of Luspatercept in People With Anemia Luspatercept - Anemia, Chronic Kidney Disease | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2026-07-20 | 2026-10-13 |
| A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East Luspatercept - β-thalassemia | Recruiting | Bristol-Myers Squibb | 200 | 2026-06-26 | 2026-08-19 | |
| Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies Luspatercept, Epoetin - Luspatercept, Epoetin | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 90 | 2026-06-15 | 2026-06-09 |
| Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis Luspatercept, Control - Luspatercept, Poor Erythroid Engraftment | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 196 | 2026-05-01 | 2026-04-20 |
| The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCT Luspatercept - HSCT | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2026-03-14 | 2026-03-04 |
| A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain Erythropoiesis-stimulating agents (ESAs), Luspatercept, Lenalidomide - Lower-risk Myelodysplastic Syndromes (TD LR-MDS) | Active not recruiting | Bristol-Myers Squibb | 1300 | 2026-02-02 | 2026-10-01 | |
| Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients Luspatercept combined with low-dose thalidomide, Luspatercept plus placebo - Transfusion-dependent β-thalassemia Patients | Phase 2 | Recruiting | Rongrong Liu | 78 | 2026-02-01 | 2026-01-13 |
| Luspatercept in Patients Affected With Rare Inherited Anemias Reblozyl - Hereditary Red Blood Cell Disorder (Disorder) | Phase 2 | Not yet recruiting | EuroBloodNet Association | 45 | 2026-01-15 | 2026-01-12 |
| Luspatercept + Darbepoetin in MDS Luspatercept, Darbeopoetin - MDS (Myelodysplastic Syndrome) | Phase 2 | Recruiting | Yale University | 60 | 2025-12-16 | 2026-09-14 |
| Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) Luspatercept - Acute Leukemia | Phase 1 / Phase 2 | Recruiting | Zhujiang Hospital | 46 | 2025-10-01 | 2026-01-23 |
| Treatment of Transfusion-dependent Nonsevere Aplastic Anemia With Luspatercept: a Multicenter Prospective Clinical Study Luspatercept, Luspatercept combine with Deferasirox - Transfusion-dependent Non-severe Aplastic Anemia | Not applicable | Not yet recruiting | The First Affiliated Hospital of Zhejiang Chinese Medical University | 90 | 2025-05-20 | 2025-05-11 |
| Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China Luspatercept - Myelodysplastic Syndromes | Completed | Bristol-Myers Squibb | 88 | 2025-04-18 | 2026-05-19 | |
| AZA+Lus VS AZA Monotherapy in HR-MDS Azacitidine (AZA), Luspatercept - Higher-risk Myelodysplastic Syndrome | Phase 3 | Not yet recruiting | Peking Union Medical College Hospital | 86 | 2025-04-01 | 2025-04-15 |
| Luspatercept for Clonal Cytopenias of Uncertain Significance Luspatercept - CCUS Clonal Cytopenia of Undetermined Significance, Anemia | Phase 2 | Recruiting | Weill Medical College of Cornell University | 50 | 2025-03-25 | 2026-03-24 |
| Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis Momelotinib, Luspatercept - Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis | Phase 2 | Recruiting | GlaxoSmithKline | 68 | 2025-02-28 | 2026-04-20 |
| A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes Luspatercept, Epoetin Alfa - Myelodysplastic Syndromes (MDS) | Withdrawn | Bristol-Myers Squibb | 2024-11-30 | 2024-10-09 |
Showing 20 of 67. Sign in to see all of them.
Myelodysplastic Syndromes (30) · Anemia (19) · beta-Thalassemia (12) · Myeloproliferative Disorders (5) · Primary Myelofibrosis (5) · Anemia, Refractory, with Excess of Blasts (4) · Anemia, Aplastic (2) · Hematologic Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Anemia, Hemolytic, Autoimmune (1) · Bone Marrow Diseases (1) · Granulosa cell tumor of the ovary (1) · Hematologic Diseases (1) · Hemoglobinopathies (1) · Leukopenia (1)
Bristol-Myers Squibb (16) · Celgene (11) · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (5) · Institute of Hematology & Blood Diseases Hospital, China (3) · Peking Union Medical College Hospital (3) · Fondazione per la Ricerca sulle Anemie ed Emoglobinopatie in Italia (2) · Nanfang Hospital, Southern Medical University (2) · National Cancer Institute (NCI) (2) · Associazione Qol-one (1) · Bing Han (1) · EuroBloodNet Association (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · Fondazione Italiana Sindromi Mielodisplastiche-ETS (1) · GWT-TUD GmbH (1) · GlaxoSmithKline (1)
United States (24) · Italy (21) · China (19) · Germany (14) · France (11) · Greece (10) · Canada (9) · Spain (9) · United Kingdom (7) · Taiwan (6) · Turkey (Türkiye) (6) · Australia (5) · Belgium (5) · Japan (5) · Lebanon (5)
Qifa Liu (2) · Abhishek A. Mangaonkar, M.B.B.S. (1) · Amit Oza, M.D. (1) · Anne Sophie Kubasch, Dr. (1) · Bing Bing, PhD (1) · Bruno Fattizzo, MD (1) · Daniela Cilloni, MD (1) · Esther Oliva, MD (1) · Guillermo Garcia-Manero, M D (1) · Jeevan Shetty, MD (1) · Jerald P Radich (1) · Jianpei Fang, Dr. (1)
PMID 30617198, PMID 28870615, PMID 33570654, PMID 35998303, PMID 36505885, PMID 37311468, PMID 37704579, PMID 41857682, PMID 20424252, PMID 24715706, PMID 28096091, PMID 29895954, PMID 30504333, PMID 30602619, PMID 31914241, PMID 32089218, PMID 32212518, PMID 34002031, PMID 36007538, PMID 36635381, PMID 36902217, PMID 36948565, PMID 37222267, PMID 37345627, PMID 37517825, PMID 37606495, PMID 37782758, PMID 38013593, PMID 38029356, PMID 38820422, PMID 39038479, PMID 39947215, PMID 39991012, PMID 40377899, PMID 40875596, PMID 41549790, PMID 42057135
2014 (2), 2015 (2), 2017 (1), U10CA180863 (1), U10CA180888 (1)